SAB Biotherapeutics, Inc. Common Stock (SABS) Stock
Key stats
- Market cap
- $235.65M
- Price / Earnings ratio
- -17.7x
- EPS (TTM)
- -$0.64
- Volume
- Loading
- 52-week high
- $5.15
- 52-week low
- $2.10
Source: third-party data provider, as of October 17, 2026
Compare with SABS
Recent news

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
SABS

SAB Biotherapeutics Q2 Earnings Call Highlights
SAB Biotherapeutics Q2 Earnings Call Highlights
SABS

SAB Biotherapeutics Q1 Earnings Call Highlights
SAB Biotherapeutics Q1 Earnings Call Highlights
SABS
Technical indicators
- RSI 14
- 28.44
- MACD 12/26/9
- -0.23
- EMA 9 of MACD
- -0.19
- MACD histogram
- -0.04
- SMA 50
- $3.44
- Price below SMA 50
- EMA 50
- $3.30
- Price below EMA 50
- SMA 200
- $3.73
- Price below SMA 200
- EMA 200
- $3.60
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
SABS

SAB Biotherapeutics Q2 Earnings Call Highlights
SAB Biotherapeutics Q2 Earnings Call Highlights
SABS

SAB Biotherapeutics Q1 Earnings Call Highlights
SAB Biotherapeutics Q1 Earnings Call Highlights
SABS
About SAB Biotherapeutics, Inc. Common Stock
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Samuel J. Reich | CEO & Director | 1975 |
| Ms. Lucy To | Executive VP & CFO | 1986 |
| Dr. Christoph Bausch M.B.A., Ph.D. | Executive VP & COO | 1971 |
| Dr. Eddie Joe Sullivan Ph.D. | Co-Founder, President & Director | 1967 |
| Dr. Alexandra Kropotova M.B.A., M.D. | Executive VP & Chief Medical Officer | 1973 |
| Ms. Catherine DeRose | Vice President of Human Resources | — |
| Ms. Hua Wu Ph.D. | Senior Vice President of Product Development | — |
| Dr. Carlos N. Carillo M.Sc., Ph.D. | Senior Vice President of Regulatory Affairs | — |
| Ms. Angie Parizek | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 17, 2026
Technical indicators
- RSI 14
- 28.44
- MACD 12/26/9
- -0.23
- EMA 9 of MACD
- -0.19
- MACD histogram
- -0.04
- SMA 50
- $3.44
- Price below SMA 50
- EMA 50
- $3.30
- Price below EMA 50
- SMA 200
- $3.73
- Price below SMA 200
- EMA 200
- $3.60
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.1 | -3.4 | +3.7 | +13.4 | -8.0 | -2.1 | -14.3 | -15.4 |



